These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 17645699)

  • 1. Expression of the melatonin receptor (MT) 1 in benign and malignant human bone tumors.
    Toma CD; Svoboda M; Arrich F; Ekmekcioglu C; Assadian O; Thalhammer T
    J Pineal Res; 2007 Sep; 43(2):206-13. PubMed ID: 17645699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) in HCC70 breast cancer cells and effects of treatment with gonadotropin-releasing hormone on RANKL expression.
    Schubert A; Schulz H; Emons G; Gründker C
    Gynecol Endocrinol; 2008 Jun; 24(6):331-8. PubMed ID: 18584413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Receptor activator of nuclear factor-kappaB ligand (RANKL) directly modulates the gene expression profile of RANK-positive Saos-2 human osteosarcoma cells.
    Mori K; Berreur M; Blanchard F; Chevalier C; Guisle-Marsollier I; Masson M; Rédini F; Heymann D
    Oncol Rep; 2007 Dec; 18(6):1365-71. PubMed ID: 17982618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Megakaryocytes modulate osteoblast synthesis of type-l collagen, osteoprotegerin, and RANKL.
    Bord S; Frith E; Ireland DC; Scott MA; Craig JI; Compston JE
    Bone; 2005 May; 36(5):812-9. PubMed ID: 15794927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate-specific antigen stimulates osteoprotegerin production and inhibits receptor activator of nuclear factor-kappaB ligand expression by human osteoblasts.
    Yonou H; Horiguchi Y; Ohno Y; Namiki K; Yoshioka K; Ohori M; Hatano T; Tachibana M
    Prostate; 2007 Jun; 67(8):840-8. PubMed ID: 17394194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Regulation of receptor activator of nuclear factor kappaB ligand and osteoprotegerin expression by prostaglandin E2 in osteoblastic-like cells].
    Wang BL; Zheng F; Qiu MC
    Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(28):1992-6. PubMed ID: 19062743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased RANKL expression is related to tumour migration and metastasis of renal cell carcinomas.
    Mikami S; Katsube K; Oya M; Ishida M; Kosaka T; Mizuno R; Mochizuki S; Ikeda T; Mukai M; Okada Y
    J Pathol; 2009 Aug; 218(4):530-9. PubMed ID: 19455604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Osteoprotegerin and receptor activator of nuclear factor kappa B ligand mRNAs expression in BMSCs of glucocorticoid-induced necrosis of the femoral head patients].
    Wang J; Gao H; Wang K; Li W; Shi Z; Zhang M
    Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2009 Jul; 23(7):777-80. PubMed ID: 19662974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone stromal cells in pagetic bone and Paget's sarcoma express RANKL and support human osteoclast formation.
    Sun SG; Lau YS; Itonaga I; Sabokbar A; Athanasou NA
    J Pathol; 2006 May; 209(1):114-20. PubMed ID: 16482498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estrogen sulfotransferase (SULT1E1) expression in benign and malignant human bone tumors.
    Svoboda M; Thalhammer T; Aust S; Arrich F; Assadian O; Toma CD
    J Surg Oncol; 2007 Jun; 95(7):572-81. PubMed ID: 17230544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes.
    Armstrong AP; Miller RE; Jones JC; Zhang J; Keller ET; Dougall WC
    Prostate; 2008 Jan; 68(1):92-104. PubMed ID: 18008334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Adiponectin regulates the expression of osteoprotegerin and receptor activator of nuclear factor-kappaB ligand in human osteoblast].
    Zhang XM; Xie H; Yuan LQ; Luo XH; Liao EY
    Zhonghua Yi Xue Za Zhi; 2008 Jun; 88(22):1562-5. PubMed ID: 18956641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Profiling of chemonaive osteosarcoma and paired-normal cells identifies EBF2 as a mediator of osteoprotegerin inhibition to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis.
    Patiño-García A; Zalacain M; Folio C; Zandueta C; Sierrasesúmaga L; San Julián M; Toledo G; De Las Rivas J; Lecanda F
    Clin Cancer Res; 2009 Aug; 15(16):5082-91. PubMed ID: 19671856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Osteoprotegerin mRNA/receptor activator of NF-kappaB ligand mRNA expressions in bone tissues of glucocorticoid-induced osteonecrosis of the femoral head].
    Wang J; Wang K; Shi Z; Zhang M
    Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2008 Oct; 22(10):1161-4. PubMed ID: 18979868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osteoprotegerin mRNA is increased by interleukin-1 alpha in the human osteosarcoma cell line MG-63 and in human osteoblast-like cells.
    Vidal ON; Sjögren K; Eriksson BI; Ljunggren O; Ohlsson C
    Biochem Biophys Res Commun; 1998 Jul; 248(3):696-700. PubMed ID: 9703989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RANKL directly induces bone morphogenetic protein-2 expression in RANK-expressing POS-1 osteosarcoma cells.
    Wittrant Y; Lamoureux F; Mori K; Riet A; Kamijo A; Heymann D; Redini F
    Int J Oncol; 2006 Jan; 28(1):261-9. PubMed ID: 16328004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long wave ultrasound may enhance bone regeneration by altering OPG/RANKL ratio in human osteoblast-like cells.
    Maddi A; Hai H; Ong ST; Sharp L; Harris M; Meghji S
    Bone; 2006 Aug; 39(2):283-8. PubMed ID: 16567138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 2-methoxyestradiol-mediated anti-tumor effect increases osteoprotegerin expression in osteosarcoma cells.
    Benedikt MB; Mahlum EW; Shogren KL; Subramaniam M; Spelsberg TC; Yaszemski MJ; Maran A
    J Cell Biochem; 2010 Apr; 109(5):950-6. PubMed ID: 20082321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression profile of receptor activator of nuclear-κB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) in breast cancer.
    Owen S; Ye L; Sanders AJ; Mason MD; Jiang WG
    Anticancer Res; 2013 Jan; 33(1):199-206. PubMed ID: 23267146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glycosaminoglycans as potential regulators of osteoprotegerin therapeutic activity in osteosarcoma.
    Lamoureux F; Picarda G; Garrigue-Antar L; Baud'huin M; Trichet V; Vidal A; Miot-Noirault E; Pitard B; Heymann D; Rédini F
    Cancer Res; 2009 Jan; 69(2):526-36. PubMed ID: 19147566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.